Shares of Gland Pharma surged more than 12% in early trade on Monday after the company reported a strong set of Q4FY26 earnings, driven by robust growth in revenue, profitability, and operating margins.
As of 9:25 AM, Gland Pharma stock was trading near its 52-week high after witnessing strong buying interest from investors following the earnings announcement.
Gland Pharma Q4 Results Highlights
Gland Pharma posted a consolidated revenue of Rs 1,743 crore in the fourth quarter, up 22.3% year-on-year compared to Rs 1,425 crore reported in the corresponding quarter last year.
The company’s EBITDA rose 47.6% to Rs 513 crore against Rs 348 crore in the year-ago period, reflecting improved operational performance.
EBITDA margin expanded sharply by 500 basis points to 29.4% from 24.4% in the same quarter last year.
Net profit nearly doubled during the quarter, rising 96.6% to Rs 367 crore compared to Rs 187 crore in Q4FY25.
The board of directors also declared a final dividend of Rs 20 per share for shareholders.
Gland Pharma Share Price Performance
Following the strong Q4 earnings, Gland Pharma shares rallied over 12% in morning trade.
At 9:25 AM, the stock touched an intraday high of Rs 2,122, close to its 52-week high of Rs 2,131.
What Boosted Investor Sentiment?
Investor sentiment remained positive after Gland Pharma delivered strong growth across key financial metrics. The sharp rise in profit, significant margin expansion, and healthy revenue growth signaled improving business momentum for the pharmaceutical company.